Zillow Inc (Z)’s Spencer Rascoff Says Trulia Inc (TRLA) Is Not The Last Acquisition

Zillow Inc (NASDAQ:Z) has recently acquired its major rival Trulia Inc (NYSE:TRLA) for an astounding $3.5 billion. Zillow Inc (NASDAQ:Z)’s CEO and co-founder, Spencer Rascoff, discussed with Bloomberg’s Trish Regan about this move and  provided some insights about the company’s business strategy going forward.

Zillow Inc (NASDAQ:Z)

In the current market scene, both Zillow Inc (NASDAQ:Z) and Trulia Inc (NYSE:TRLA) do not seem to be profitable. When questioned about this, Rascoff said that it was because they chose not to be.

In his own words, “[...] We choose how profitable we want be right now, and right now we are not choosing to be very profitable. We are choosing to invest in advertising, we are spending about $75 million this year to grow the Zillow brand and grow our audience and we are investing in product development and we think those are the right things for long term shareholder value creation, but  in the near term it curbs profitability.”

Though they are now part of Zillow Inc (NASDAQ:Z), Trulia Inc (NYSE:TRLA) and StreetEasy retain their unique brand identities.

“Certain consumers gravitate to certain brands for different reasons. They like the color palette of one or another, they like a particular feature in one or another and there are a lot of media companies that adopt multiple brands [...],” he said.

Zillow Inc (NASDAQ:Z) has been on an acquisition spree in the recent years, its most recent conquests being StreetEasy for $50 million in 2013 and Trulia Inc (NYSE:TRLA) for $3.5 billion in 2014.

“Trulia would be our ninth acquisition. I’m sure that won’t be our last. [...] We have made three consumer facing acquisitions, StreetEasy, Hotpads and, soon upon closing, Trulia. So we keep looking at acquisitions and we’ll see,” Rascoff added.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!